FierceBiotech1d
Lykos accepts FDA’s view that reviving rejected MDMA therapy’s fortunes requires fresh phase 3 trial
Lykos Therapeutics may have shed three-quarters of its staff in the wake of the FDA's rejection of its MDMA candidate for ...
BioSpace1d
Lykos Announces ‘Productive’ Meeting With FDA Regarding Rejected MDMA Drug
In a short statement Friday, Lykos Therapeutics expressed optimism about a recent meeting with the regulator to discuss next ...
FDA is said to see “path forward” for ecstasy-based drug
Lykos Therapeutics, whose lead asset, midomafetamine capsules (MDMA), failed to win the FDA nod in August, said that the ...
pharmaphorum4d
Lykos CEO steps down after MDMA is rejected by FDA
Emerson has been at the helm of Lykos since 2014 and has been involved in the development of its MDMA-based midomafetamine therapy for post-traumatic stress disorder (PTSD) for more than 20 years.
ENDPOINTS NEWS4d
Lykos is op­ti­mistic about MD­MA treat­ment af­ter meet­ing with FDA
Lykos Therapeutics said it had a “productive” meeting with the FDA to discuss a path forward for its recently rejected PTSD ...
Medscape5d
MDMA Is Off the Table, So What’s Next for PTSD?
The FDA recently declined to approve MDMA-assisted therapy for PTSD, but experts said there are many other treatments on the ...
Seeking Alpha3d
FDA is said to see “path forward” for ecstasy-based drug
Lykos Therapeutics, whose lead asset, midomafetamine capsules (MDMA), failed to win the FDA nod in August, said that the regulator has indicated a path forward for the Ecstasy-based drug ...